课题基金 / 基金详情

GENE THERAPY OF GLOMERULONEPHRITIS BY GENE TRANSFER OF CELL CYCLE-RELATED GENES.

GENE THERAPY OF GLOMERULONEPHRITIS BY GENE TRANSFER OF CELL CYCLE-RELATED GENES.
通过细胞周期相关基因的基因转移进行肾小球肾炎的基因治疗。
批准号:
09557090
负责人:
TERADA Yoshio
金额:
$7.55万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B).
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 2000

项目摘要

项目成果

TERADA Yoshio的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Recent studies have revealed that mitogen-actiated protein kinase(MAPK)consists of at least three subfamilies, namely include classical MAPK(also known as ERK), stress-activated protein kinase/c-Jun N-terminal kinase(JNK), and p38 kinase. TGF-b-activating kinase(TAK)-1 is a novel MAPKKK which is reported to stimulate p38K and/or JNK pathway. To elucidate functional roles of the TAK1 pathway, we transfected its constitutive active form(TAKdN)and negative form(TAKK63W)to LLCPK1 cells. TAKdN inhibited 3H-thymidine uptake, and reduced the percentages of S and G2/M phases. TAKK63W ameliorated inhibition of 3H-thymidine uptake and the percentages of S and G2/M phases by TGF-b. Western blot analysis demonstrates that the cyclin D1 protein level was negatively regulated by overexpression of TAKdN.Moreover, overexpression of TAKdN inhibited cyclin D1 promoter activity. In contract, constitutive active MKK1, the classical p42/44 MAPK-activator, increased cyclin D1 promoter activity and protein level. Overexpression of the active form of MKK1 increased 3H-thymidine uptake, while the inactive form decreased the uptake.In conclusion, cyclin D1 promoter activity and cell cycle progression are negatively regulated by the TAK1-MKK6-p38K pathway and positively regulated by the MKK1-p42/44 MAPK pathway.
期刊论文(67)
专著(0)
科研奖励(0)
会议论文
Y.Terada, T.Okado, S.Inoshita, S.Hanada, M.Kuwahara, S.Sasaki, T.Yamamoto, F.Marumo: "Glucocorticoids stimulate p21CIP1 and arrest cell cycle in vitro and in anti-GBM glomerulonephritis."Kidney International. (in press).
Y.Terada、T.Okado、S.Inoshita、S.Hanada、M.Kuwahara、S.Sasaki、T.Yamamoto、F.Marumo:“糖皮质激素在体外和抗 GBM 肾小球肾炎中刺激 p21CIP1 并阻止细胞周期。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Y. Terada, O. Nakashima, S. Inoshita, M. Kuwahara, S. Sasaki, F. Marumo.: "TGF-β-activating kinase-1 inhibits cell cycle and expression of cyclin D1 and A in LLC-PK1 cells."Kidney International. 56. 1378-1390 (1999)
Y. Terada、O. Nakashima、S. Inoshita、M. Kuwahara、S. Sasaki、F. Marumo.:“TGF-β 激活激酶-1 抑制 LLC-PK1 细胞中的细胞周期和细胞周期蛋白 D1 和 A 的表达。 “国际肾脏病杂志。56。1378-1390 (1999)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Y.Terada et al: "Overexpression of cell cycle inbibitors (p161NK4 and p21 cipl) and cyclin D1 using adenovirus regulates proliferation of rat mesangial cells." Journal of American Society of Nephrology. 8. 51-60 (1997)
Y.Terada 等人:“使用腺病毒过度表达细胞周期抑制剂(p161NK4 和 p21 cipl)和细胞周期蛋白 D1 可调节大鼠系膜细胞的增殖。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
S.Inoshita et al: "Roles of E2F1 in mesangial cell cycle in vitro"Kidney International. 56. 2086-2095 (1999)
S.Inoshita 等人:“E2F1 在体外系膜细胞周期中的作用”Kidney International。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
56
    Regulation of mitochondrial function for protection of acute kidney
    • 批准号:
      15K15331
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2015
    • 负责人:
      TERADA Yoshio
    • 依托单位:
    Mitophagy and acute kidney injury
    • 批准号:
      25670412
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2013
    • 负责人:
      TERADA Yoshio
    • 依托单位:
    Regulation of autophagy in acute kidney injury treatment
    • 批准号:
      23390227
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.31万
    • 财政年份:
      2011
    • 负责人:
      TERADA Yoshio
    • 依托单位:
    Involvement of autopgaly and lysosomal system in renal diseases
    • 批准号:
      21659214
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.04万
    • 财政年份:
      2009
    • 负责人:
      TERADA Yoshio
    • 依托单位:
    国内基金
    海外基金
    槐耳联合CDK4/6抑制剂调控Cyclin D1-CDK4/6-Rb通路在乳腺癌中的作用及机制研究
    新型铜载体天然产物Chalkphomycin通过ATM酶-CHK2-Cyclin D1轴抗黑色素瘤作用机制研究
    • 批准号:
      2025JJ80302
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      龚邦
    • 依托单位:
    青蒿琥酯调控Nrf2/HO-1-Cycin D1/CDK4-pRB信号轴诱导甲状腺相关眼病成纤维细胞衰老的机制研究
    • 批准号:
      2025JJ60577
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      刘静远
    • 依托单位:
    Cyclin D1-Dicer正反馈回路调控胆管癌细胞基因组CpG位点从头甲基化的机制
    • 批准号:
      LQ23C060003
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2023
    • 负责人:
      齐永强
    • 依托单位: